Longevity & mitochondrial · Evidence comparison
MOTS-c vs SS-31 (Elamipretide)
Two mitochondria-focused peptides marketed for energy and anti-aging — but their evidence and regulatory status diverge sharply.
MOTS-c
SS-31 (Elamipretide)
Headline claim shown. Grades are claim-specific — see the full breakdown below.
The evidence, side by side
Every graded claim from each brief. Grades are read straight from the source-checked briefs — one molecule can be strong for one use and weak for another.
Mitochondrial / metabolic (exercise mimetic)
MOTS-c
Evidence grades
Mitochondrial / longevity (mitochondria-targeted peptide)
SS-31 (Elamipretide)
Evidence grades
Regulatory status at a glance
MOTS-c
Not FDA-approved and not approved by any major regulator for any use. MOTS-c is a naturally occurring 16-amino-acid peptide encoded within the mitochondrial genome (the 12S rRNA gene); as a therapeutic it is investigational. Most evidence is preclinical (cells and animals) plus human biomarker studies; an early-phase (Phase 2a) human trial in adults with prediabetes and overweight/obesity is underway, but no large completed human efficacy trials exist. Synthetic MOTS-c sold online for fat loss, performance, or anti-aging is gray-market / 'research only' material, and those uses are not established in humans. Status varies by country and can change; this is not medical or legal advice.
SS-31 (Elamipretide)
FDA-approved as Forzinity (elamipretide HCl) — granted accelerated approval on September 19, 2025 for the treatment of Barth syndrome in adult and pediatric patients weighing at least 30 kg; this is the first approved therapy for that ultra-rare genetic mitochondrial disease. As an accelerated approval, continued approval may be contingent on confirmatory trials. It is NOT approved for any other condition: its Phase 3 trial in primary mitochondrial myopathy (MMPOWER-3) did not meet its primary endpoints, and its development in other conditions (e.g., heart failure, dry age-related macular degeneration) has been largely unsuccessful. The 'SS-31' sold online for anti-aging, energy, and 'mitochondrial repair' is gray-market / 'research only' material, not the approved drug, and those uses are unstudied in humans. A mitochondria-targeted tetrapeptide that binds cardiolipin on the inner mitochondrial membrane. Status varies by country and can change; this is not medical or legal advice.
Key differences
- SS-31 (elamipretide) is now FDA-approved (Forzinity) for the ultra-rare Barth syndrome (graded S for that use); MOTS-c is investigational, with no approval.
- Both are graded B for anti-aging or energy in healthy adults — that use is unproven for each.
- SS-31's larger trials in more common mitochondrial disease (MMPOWER-3) largely failed (graded C for that broader use); MOTS-c's metabolic evidence is preclinical (A), with human trials just beginning.
- The 'SS-31' and MOTS-c sold online are gray-market, not an approved drug.
The bottom line
SS-31 has a real approval, but only for one rare disease, and it failed its broader trials; MOTS-c is earlier still — strong in animals, unproven in people. We don't recommend either; the anti-aging marketing for both rests on lab data, not human results.
PeptideIQ Base does not recommend, rank, or endorse any peptide, dose, or product. We grade the strength of the evidence so you can read it for yourself.
Read the full briefs
Full evidence brief
MOTS-c →
A peptide your own mitochondria make, which rises with exercise and improves metabolism and insulin sensitivity in animals; it's one of the most scientifically interesting 'exercise mimetic' compounds, but human evidence is still early — strong mouse data and human biomarker studies, with efficacy trials only now beginning — so the fat-loss and anti-aging marketing is ahead of the proof.
Full evidence brief
SS-31 (Elamipretide) →
A mitochondria-targeting peptide that concentrates in the cell's energy machinery and binds cardiolipin; it just became FDA-approved (as Forzinity) for the ultra-rare Barth syndrome, but its large trials in more common conditions — including primary mitochondrial myopathy — largely failed, so the popular 'anti-aging / mitochondrial repair' marketing rests on lab data, not human proof.
See every peptide, graded on one page
The Peptide Evidence Report Card grades all our peptides S+ to C on the strength of the human evidence. Research only — no hype, never a recommendation.
Get the report card →